Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Cancer Surgery
Complex treatment of neuroblastoma
A clinical guide to the complex treatment of neuroblastoma in Turkey, detailing risk stratification from low to high risk. Learn how multidisciplinary protocols combine induction chemotherapy, surgical resection, autologous stem cell transplantation, radiotherapy, and anti-GD2 immunotherapy. Review approximate European cost comparisons, recovery milestones during intensive treatment cycles, expected scan outcomes, and vital questions for pediatric oncology centers.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Cancer Surgery
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Complex Treatment of Neuroblastoma
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Complex treatment of neuroblastoma in Turkey: what it is and how it works
The complex treatment of neuroblastoma refers to the specialised, multi-phase medical strategy used to manage neuroblastoma, the most common extracranial solid tumour of early childhood. Arising from immature nerve cells (neuroblasts) of the sympathetic nervous system, these tumours most frequently develop in the adrenal glands above the kidneys, or along nerve tissue in the abdomen, chest, neck, or pelvis. Because neuroblastoma exhibits diverse clinical behaviours—ranging from spontaneous regression in infants to highly aggressive metastatic spread—effective management cannot rely on a single intervention. Instead, care requires a multimodal regimen combining systemic chemotherapy, precise surgical resection, high-dose consolidation with stem cell rescue, radiation therapy, and targeted immunotherapy.
Hospitals offering the complex treatment of neuroblastoma in Turkey bring together paediatric oncologists, paediatric surgical oncologists, radiation therapists, and bone marrow transplant teams within comprehensive oncology departments. Treatment is tailored according to international risk-stratification systems that assess tumour biology, child age, and genetic markers. For parents researching therapeutic pathways for solid tumours, our overview of oncology treatments in Turkey provides further context on specialized care standards.
How is neuroblastoma staged and risk-stratified?
Before any therapy begins, clinicians must establish the precise stage and biological risk profile of the tumour. The International Neuroblastoma Risk Group Staging System (INRGSS) classifies tumours before surgery using Image-Defined Risk Factors (IDRFs), which identify whether the mass encases critical blood vessels or vital organs:
- Stage L1: Localised disease without image-defined risk factors, confined to one body compartment.
- Stage L2: Locoregional disease with one or more image-defined risk factors, indicating surgical complexity.
- Stage M: Distant metastatic disease involving bone marrow, distant lymph nodes, liver, or bones.
- Stage MS: Metastatic disease in children younger than 18 months, restricted to skin, liver, or bone marrow.
Risk stratification divides patients into low-risk, intermediate-risk, and high-risk categories. This classification relies not only on anatomical stage and age, but crucially on tumour genetics. The amplification of the MYCN oncogene, chromosome 1p or 11q deletions, and DNA ploidy fundamentally dictate tumour aggressiveness. Low-risk patients may require only careful observation or gentle surgery, whereas high-risk patients require the complete multimodal protocol to overcome systemic disease resistance.
Does complex treatment of neuroblastoma work? Evidence and protocol outcomes
Modern international clinical trials conducted by cooperative oncology groups—such as SIOP Europe (SIOPEN) and the Children's Oncology Group (COG)—have significantly improved outcomes over recent decades. For children diagnosed with low-risk and intermediate-risk neuroblastoma, event-free survival rates exceed 85 to 90 percent using conservative surgery and moderate-intensity chemotherapy. In these cohorts, treatment de-escalation has successfully reduced long-term toxicities without compromising disease control.
For high-risk neuroblastoma, the disease historically carried a guarded prognosis. However, the introduction of intensive multimodal regimens has shifted long-term survival substantially. Clinical evidence confirms that high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) improves event-free survival compared to conventional chemotherapy alone. Furthermore, landmark phase III studies established that maintenance therapy with anti-GD2 monoclonal antibodies (such as dinutuximab), combined with cytokines and isotretinoin, increases two-year event-free survival by approximately 20 percentage points over isotretinoin alone. Nevertheless, clinical oncology acknowledges that high-risk neuroblastoma remains challenging, particularly in cases of refractory progression or late relapse, where salvage trials or novel targeted agents are actively investigated.
Multimodal protocol vs surgical resection alone in neuroblastoma
Understanding why a multimodal approach is necessary requires comparing it against single-modality strategies. Unlike adult oncological procedures such as a lumpectomy for localised breast tissue or primary removal of colon cancer, neuroblastoma in young children possesses an inherent propensity for early microscopic dissemination. Resection alone cannot eliminate circulating neuroblastoma cells or micrometastases already seeded in bone marrow.
| Method | Best suited to | Typical limits |
|---|---|---|
| Surgical resection alone | Localised, low-risk tumours without image-defined risk factors or MYCN amplification | Cannot treat microscopic residual disease, lymph node involvement, or distant metastases |
| Moderate chemotherapy with delayed surgery | Intermediate-risk neuroblastoma with favourable histology and biology | Insufficient potency for biologically aggressive, metastatic, or MYCN-driven tumours |
| Intensive multimodal protocol | High-risk neuroblastoma, stage M disease, or tumours harbouring MYCN amplification | Demanding therapeutic course; requires prolonged hospital stays and specialist paediatric intensive care |
Clinicians emphasize that surgery in high-risk disease is timed strategically after induction chemotherapy has shrunk the primary mass and reduced vascular encasement, transforming previously unresectable tumours into operable lesions.
Complex treatment of neuroblastoma cost in Turkey compared with the UK, US and Germany
The financial commitment for paediatric oncology care varies significantly by destination, protocol intensity, and individual clinical complications. The table below presents approximate cost ranges for complete high-risk treatment packages across international destinations.
| Country | Approximate cost range |
|---|---|
| Turkey | €45,000 – €160,000 |
| United Kingdom | €90,000 – €280,000 |
| United States | €180,000 – €550,000 |
| Germany | €85,000 – €260,000 |
Several specific variables determine the final complex treatment of neuroblastoma cost. High-risk protocols require extensive inpatient isolation days during stem cell transplantation, substantial blood product support, and expensive pharmaceuticals. In particular, anti-GD2 immunotherapy represents a major driver of the total complex treatment of neuroblastoma price, as these specialized biological drugs carry substantial acquisition costs globally. Additional factors influencing expenses include the complexity of abdominal or thoracic vascular surgery, extended stays in the paediatric intensive care unit (PICU), and routine molecular diagnostics including MIBG scans and next-generation sequencing.
Comprehensive medical travel packages typically incorporate hospitalisation fees, surgical theatre charges, consultant oncologist and anaesthetist fees, initial staging scans, pathology reviews, and airport transfers. Families should request a detailed, written itemisation before initiating therapy to clarify medication inclusion thresholds. Families seeking financial clarity can request a free quote with a full medical review.
What are the stages of complex treatment for high-risk neuroblastoma?
The treatment of high-risk neuroblastoma is structured into three continuous phases: induction, consolidation, and maintenance. Each stage targets tumour cells through distinct biological mechanisms:
- Induction chemotherapy: Patients receive multiple intensive cycles combining alkylating agents and platinum-based compounds (such as cisplatin, etoposide, vincristine, cyclophosphamide, and doxorubicin). The goal is to eradicate metastatic disease and shrink the primary tumour. During this phase, peripheral blood stem cells are harvested from the child via apheresis and cryopreserved for later rescue.
- Surgical resection: Once induction chemotherapy has maximally reduced tumour volume, a paediatric surgical oncologist performs radical resection to remove the primary tumour, carefully dissecting around major abdominal blood vessels.
- Consolidation therapy: The child receives myeloablative high-dose chemotherapy (such as busulfan and melphalan) to eliminate remaining microscopic tumour cells. Because this ablates bone marrow function, the cryopreserved autologous stem cells are reinfused to rebuild blood counts. Following stem cell recovery, external beam radiotherapy is delivered to the initial tumour bed to prevent local recurrence.
- Maintenance and immunotherapy: After recovery from consolidation, patients receive targeted immunotherapy using monoclonal anti-GD2 antibodies (such as dinutuximab), administered alongside cytokines to stimulate immune destruction of neuroblastoma cells, combined with oral isotretinoin to induce differentiation of any residual cells.
Who is a candidate for intensive multimodal therapy?
Candidate selection for complex multimodal protocols is determined by internationally recognised risk criteria rather than parental preference. Candidates for full-intensity treatment include:
- Children aged 18 months or older with stage M metastatic disease.
- Infants or children of any age with MYCN-amplified tumours, regardless of anatomical stage.
- Children with stage L2 tumours exhibiting unfavourable histology or high-risk genetic deletions.
Conversely, young infants with stage MS disease showing favourable biology frequently experience spontaneous tumour regression and are candidates for vigilant clinical monitoring rather than cytotoxic therapy. Patients with low-risk, completely resectable tumours do not require intensive chemotherapy or stem cell transplant. Children with severe pre-existing renal, hepatic, or cardiac impairment require modified chemotherapeutic dosages to prevent irreversible organ toxicity. Comprehensive baseline assessments—including echocardiography, audiometry, renal clearance tests, and 123I-MIBG scintigraphy—are mandatory before initiating therapy.
Treatment duration in Turkey and pediatric recovery milestones
The overall timeline for completing a high-risk neuroblastoma protocol spans between 12 and 18 months. Because therapy is delivered in scheduled cycles separated by rest intervals, international families typically structure their stay in Turkey either as an extended residency or across phased visits coordinated with their home medical team.
Understanding complex treatment of neuroblastoma recovery involves monitoring distinct physiological milestones after each phase:
- Between induction cycles (weeks 1–12): Following each chemotherapy block, blood counts drop sharply. Recovery of neutrophils and platelets typically requires 10 to 18 days, during which strict isolation and infection precautions are observed.
- Post-surgical recovery (weeks 14–16): Inpatient hospitalisation after tumour resection generally lasts 5 to 10 days. The surgical team monitors gut motility, wound healing, and vascular integrity before starting consolidation.
- Stem cell transplant recovery (weeks 18–24): Engraftment of reinfused autologous stem cells typically occurs between 14 and 21 days after reinfusion in a specialized laminar air-flow room. Full immune recovery continues over several months.
- Immunotherapy and maintenance (months 7–15): Dinutuximab cycles are given monthly over 5 to 6 months. Recovery between immunotherapy infusions involves managing neuropathic pain, capillary leak, and fever, with children usually monitored closely in the outpatient clinic.
Monitoring remission and scans: what do before-and-after results show?
In paediatric solid tumours, evaluating results does not involve cosmetic changes, but rather rigorous functional and radiological measurements. Before-and-after evaluations rely on sequential imaging and biological markers to determine remission status:
- 123I-MIBG scans: MIBG scintigraphy specifically tracks neuroblastoma avidity. Pre-treatment scans show intense uptake in primary lesions and skeletal metastases; successful treatment results in complete resolution of MIBG-avid skeletal lesions, scored via SIOPEN or Curie semi-quantitative systems.
- Contrast-enhanced MRI and CT scans: Cross-sectional imaging documents tumour volume shrinkage after induction. Clinicians look for calcification and maturation of residual soft-tissue masses. Importantly, a residual mass on CT or MRI does not always represent active malignancy; it often consists of non-viable scar tissue, necrotic debris, or benign ganglioneuroma.
- Bone marrow aspirates and trephine biopsies: Bilateral marrow samples must confirm clearance of microscopic tumour infiltrates.
- Urinary catecholamine metabolites: Vanillylmandelic acid (VMA) and homovanillic acid (HVA) levels, which are elevated at initial diagnosis, should normalise as tumour burden diminishes.
Parents should understand that achieving complete response at the conclusion of consolidation is a major milestone, but ongoing surveillance through regular scans every three to six months remains essential during the first three years post-therapy.
Risks, acute toxicities and long-term side effects
The high therapeutic intensity required to treat neuroblastoma carries substantial acute and late side effects, documented by international bodies including the NHS, SIOP Europe, and the Children's Oncology Group:
- Febrile neutropenia and sepsis: Severe bone marrow suppression elevates the risk of life-threatening bacterial and fungal infections, necessitating prompt intravenous broad-spectrum antibiotic therapy.
- Ototoxicity: Platinum-based agents (especially cisplatin) can cause irreversible high-frequency hearing loss, monitored through baseline and routine audiograms.
- Veno-occlusive disease: High-dose conditioning regimens prior to stem cell transplant can cause hepatic sinusoidal obstruction syndrome, presenting with hepatomegaly, jaundice, and fluid retention.
- Cardiotoxicity and renal impairment: Doxorubicin can affect cardiac muscle function over time, while ifosfamide and platinum compounds may lead to tubular nephropathy.
- Immunotherapy toxicities: Anti-GD2 antibody infusions cause significant neuropathic pain due to GD2 expression on peripheral nerve fibres, requiring continuous intravenous opioid infusions, alongside risks of capillary leak syndrome and allergic reactions.
- Late effects: Survivors require multi-year endocrine follow-up for growth hormone deficiency, thyroid dysfunction, pubertal delay, and monitoring for secondary malignancies.
How to choose a pediatric oncology center and red flags to watch for
Managing advanced neuroblastoma demands institutional excellence across multiple subspecialties. When evaluating hospitals for complex treatment of neuroblastoma Turkey care, parents must verify specific structural capabilities:
- Multidisciplinary tumour board: Look for regular paediatric oncology tumor boards comprising certified paediatric oncologists, paediatric surgical oncologists with experience in vascular neuroblastoma resection, paediatric radiologists, and paediatric pathologists.
- JACIE-accredited transplant unit: The facility should maintain a dedicated paediatric bone marrow transplant unit equipped with positive-pressure HEPA-filtered rooms and dedicated paediatric nursing teams.
- On-site PICU: A fully equipped paediatric intensive care unit staffed by dedicated paediatric intensivists must be present within the same hospital building.
- Nuclear medicine and radiotracer access: The hospital must have on-site access to MIBG scanning and PET-CT imaging for prompt disease tracking.
Red flags to avoid include clinics operating without an in-house paediatric intensive care unit, adult facilities treating paediatric patients without dedicated paediatric specialists, centres unable to perform molecular MYCN testing, and coordinators offering promises of guaranteed cures or quoting fixed prices without seeing full pathology and imaging records.
Questions to ask the oncology team:
- How many children with neuroblastoma does your multidisciplinary team treat annually?
- What international protocol (such as SIOPEN or COG) does your department follow?
- Is your bone marrow transplant unit dedicated exclusively to paediatric patients?
- What support services are available if my child requires urgent intensive care during chemotherapy?
- Does your quotation cover all rounds of anti-GD2 immunotherapy, stem cell rescue, and supportive blood products?
- How will follow-up imaging and scan reports be shared with our home oncologist after discharge?
Families can learn more about international patient logistics by reading how it works or submit recent diagnostic reports through our free quote portal to receive a clinical evaluation.
Conditions treated with Complex Treatment of Neuroblastoma
Hospitals with Oncology in Turkey
Frequently asked questions
The complex treatment of neuroblastoma is a multi-phase paediatric oncology protocol designed for nerve tissue tumours arising in the adrenal glands or sympathetic chain. Treatment combines systemic chemotherapy, surgical tumour resection, high-dose consolidation with autologous stem cell rescue, radiation therapy, and targeted anti-GD2 immunotherapy to target primary tumours and prevent metastatic recurrence.
Yes, modern risk-stratified protocols significantly improve clinical outcomes. Low-risk and intermediate-risk disease achieve cure rates exceeding 85 to 90 percent with surgery and moderate chemotherapy. For high-risk neuroblastoma, multimodal protocols combining high-dose consolidation, stem cell transplant, and anti-GD2 immunotherapy have raised two-year event-free survival by approximately 20 percent compared to conventional chemotherapy alone.
Approximate costs in Turkey range from €45,000 to €160,000, compared with €85,000 to €280,000 in Western Europe and higher in the US. Total expenses depend on whether high-dose chemotherapy with autologous stem cell transplantation and anti-GD2 immunotherapy are required. The treating hospital confirms itemised costs in a formal written quotation.
Imaging tracks biological remission rather than cosmetic changes. 123I-MIBG scans demonstrate the clearance of active radiotracer uptake in primary sites and bone metastases. Contrast CT or MRI scans document primary tumour shrinkage and calcification. A residual mass on scans often consists of benign, inactive fibrous tissue rather than viable cancer cells.
Recovery intervals vary by treatment phase. Blood counts typically take 10 to 18 days to recover after each induction chemotherapy cycle. Following high-dose chemotherapy and autologous stem cell reinfusion, marrow engraftment requires two to three weeks in sterile isolation. Outpatient recovery between monthly immunotherapy cycles takes about two to three weeks.
Chemotherapy itself is not painful, though it causes nausea, fatigue, and mouth ulcers. Tumour resection is performed under general anaesthesia with comprehensive postoperative pain control. During anti-GD2 immunotherapy infusions, nerve irritation can cause sharp pain, which paediatric oncology teams manage proactively with continuous intravenous analgesia, antihistamines, and anti-inflammatory medications.
Long-term outcomes depend strictly on the biological risk group. Children with low-risk and intermediate-risk tumours achieve remission rates above 85 to 90 percent. High-risk neuroblastoma carries greater biological persistence; long-term survival has substantially improved with immunotherapy and tandem transplants, though close surveillance with scans is vital to detect any early recurrence.
Acute risks include severe febrile neutropenia, infection, mouth sores, bleeding, and capillary leak syndrome during immunotherapy. Potential long-term toxicities involve high-frequency hearing loss from cisplatin, decreased renal or cardiac function, growth and endocrine alterations, and a small risk of secondary malignancies. Paediatric oncologists conduct ongoing screening to manage late effects.
Surgery alone is effective only for small, localized, low-risk neuroblastomas without high-risk genetic mutations. Because high-risk neuroblastoma spreads microscopically through the bloodstream and lymphatic system, surgical excision alone cannot prevent recurrence. Complete multimodal treatment is essential to eliminate circulating tumour cells and distant metastases throughout the bone marrow.
Because complete high-risk treatment spans 12 to 18 months, families typically arrange extended stays or multiple planned visits. Induction blocks and surgical resection require about six to eight weeks. The stem cell transplant requires four to six continuous inpatient weeks. Many families stay locally for initial phases before coordinating maintenance.
Patient stories